Hemophagocytic Histiocytic Sarcoma Case Study: Forrest
A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells.
Splenic Hemangiosarcoma Case Study: Pita
With a combination approach that included FidoCure® therapy, Pita lived for a year following a hemoabdomen and diagnosis of splenic hemangiosarcoma.
Research featured in The Cancer Letter
We were thrilled to see our recent Nature paper featured in last week’s issue of The Cancer Letter! Our multi-year study has compared canine and human cancer journeys and revealed predictive biomarkers and beneficial therapeutics that impact both sides of the leash. We are honored to be recognized in The Cancer Letter, a leading publication for oncology professionals […]
Genomics and the promise to transform cancer treatment on both ends of the leash: National DNA Day
I am thrilled to join you all in commemorating National DNA Day and the role that genomics, the foundation of precision medicine, play in the future of cancer treatment.
Anal Sac Adenocarcinoma Case Study: Brady
Amelanotic Melanoma Case Study: Phinn
With the help of FidoCure® therapy, Phinn has lived a great quality of life for over 18 months after his initial diagnosis of amelanotic melanoma and is still going strong!
Thrive Pet Healthcare and FidoCure® Announce An Expansive Pet Precision Health Partnership
Strategic partnership leveraging FidoCure’s precision medicine platform advances joint vision for providing personalized, accessible veterinary cancer care
Get to Know: Chase Schwalbach, Chief Product Officer, FidoCure
Tell us about your background I grew up on the Ohio/Kentucky border, from a relatively modest background. My mom worked 3 jobs to support me and my 2 siblings, and I didn’t step onto a plane until I graduated college. I went to school at Morehead State University in Kentucky and got an undergraduate degree […]
Transitional Cell Carcinoma Case Study: Ruby
With the help of FidoCure® therapy, Ruby had a great quality of life for 2 years after her initial diagnosis of transitional cell carcinoma.
Medical Brief: Treatment of Canine Cutaneous Epitheliotropic T-cell lymphoma with Olacitinib
Jeylan Aslan, Michael A. Shipstone and Louise M. Sullivan Vet Dermatol. 2021 May 25. doi: 10.1111/vde.12976 This case study reviews the use of olacitinib to treat cutaneous epitheliotropic T-cell lymphoma (CETL).